Rhythm Pharmaceuticals (NASDAQ: RYTM) reported Q2 EPS of ($0.89), $0.07 better than the analyst estimate of ($0.96). Revenue for the quarter came in at $9.07 million versus the consensus estimate of $2.57 million.

For earnings history and earnings-related data on Rhythm Pharmaceuticals (RYTM) click here.